---
title: "Circle Pharma raises $92.5 million in Series E funding led by Column Group"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299181925.md"
description: "Circle Pharma secured $92.5 million in Series E funding led by The Column Group, with participation from Nextech Invest, RA Capital, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, an oral macrocyclic cyclin D1 RxL inhibitor, into early clinical development for ER+ breast cancer, expected to begin in Q1 2027."
datetime: "2026-09-16T12:19:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299181925.md)
  - [en](https://longbridge.com/en/news/299181925.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299181925.md)
generator: "portal-rs"
---

# Circle Pharma raises $92.5 million in Series E funding led by Column Group

-   Circle Pharma raised USD 92.5 million in an oversubscribed Series E private financing led by The Column Group. \* New and existing investors included Nextech Invest, RA Capital, Euclidean Capital, Eli Lilly, among others. \* Proceeds will advance CID-165, an oral macrocyclic cyclin D1 RxL inhibitor, into early clinical development for ER+ breast cancer. \* CID-165 is expected to enter clinical development in Q1 2027. \* Circle Pharma is a clinical-stage biotech developing targeted macrocycle cancer therapies, including a pipeline of cyclin-targeted macrocycles. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Circle Pharma Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Purchased by Integrated Wealth Concepts LLC](https://longbridge.com/en/news/298698438.md)
- [Eli Lilly and QurCan sign genetic medicine deal](https://longbridge.com/en/news/299162046.md)
- [Maloon Powers Pitre Higgins & Dennehy LLC Buys Shares of 908 Eli Lilly and Company $LLY](https://longbridge.com/en/news/298282618.md)
- [FTH: Oral multi-node inhibition demonstrates strong early efficacy and tolerability in cancer trials](https://longbridge.com/en/news/298617683.md)
- [PALI: Phase II trials for a novel oral PDE4 inhibitor in UC and Crohn's are fully funded and underway](https://longbridge.com/en/news/299202156.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**